eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2026-01-28 18 October Spl Edition 70242 article Deniz M. Al-Tawalbeh 1 Wissam Al-momani 2 Amir Majdi Moh'd 2 Abdelrahman Alenaizat 2 Anas Majdi Moh’d 2 Bsher Mfarrej 2 Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan Faculty of Medicine, Yarmouk University, Irbid, Jordan Parkinson’s Disease (PD), is a neurodegenerative disease marked by motor and non-motor symptoms, with high evidence highlighting the critical role of the gut-brain axis in the disease development. Helicobacter pylori (H. pylori), a typical gastric pathogen, has been identified as a contributor to Parkinson’s Disease. Changes in H. pylori infection to gut microbiota may cause systemic inflammation and nutrient malabsorption in addition to levodopa absorption impairment which may exacerbate PD pathogenesis and worsen symptoms. This narrative review explores the correlation between H. pylori infection and PD, to bring new insight into both diseases’ pathophysiology and focus on novel therapeutic options that can inhibit H. pylori growth, enhance intestinal integrity, and influence neurodegeneration in PD. However, it is constrained by rigorous quality assessment and may be subjected to selection bias.  A comprehensive research investigating the link between H. pylori and PD was the focus of an extensive literature search that spanned the years 2005–2024 and was carried out using PubMed, Scopus, Web of Science, and Google Scholar. We combed through new information on treatments based on microbiota with relevant clinical trials, meta-analyses, and models of experimentation. H. pylori infection is common in PD patients and may play a role in systemic inflammation, small intestinal bacterial overgrowth (SIBO), reduced levodopa bioavailability, and elevated α-synuclein expression. The eradication of H. pylori has shown beneficial impacts on motor symptoms and enhanced the efficacy of levodopa. Herbal compounds including epigallocatechin gallate, baicalein, curcumin, and garlic derivatives exhibit notable antimicrobial and neuroprotective properties. Synbiotic interventions and personalized nutrient supplementation enhance gastrointestinal and neurological health. H. pylori infection in PD is a unique therapeutic target for gastrointestinal and neurological therapy. Antimicrobial therapy, dietary management, and phytomedicine may reduce inflammation, restore gut-brain balance, and enhance PD treatment outcomes. To improve patient-specific therapies, longitudinal studies and bioinformatics-guided microbiome analyses should be considered. https://biomedpharmajournal.org/vol18octoberspledition/the-convergence-of-parkinsons-disease-and-helicobacter-pylori-infection-review-article/ Gut-brain axis Helicobacter pylori Herbal remedies Levodopa Parkinson’s disease